Accera’s new Alzheimer’s therapy to be featured on 21st Century Health Television March 22, 2009 on Fox Business Network (as paid programming)
"Axona has been shown in randomized, placebo controlled clinical trials to safely improve cognitive function and memory in patients diagnosed with mild-to-moderate AD."
(EMAILWIRE.COM, March 19, 2009 ) Boca Raton, FL - Multi-Media Productions (USA), Inc. announced today that Accera and its new product Axona, a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer’s disease (AD), will be featured on 21st Century Health.
Axona has been shown in randomized, placebo controlled clinical trials to safely improve cognitive function and memory in patients diagnosed with mild-to-moderate AD. It provides an alternative energy source for the brain so that neurons can function properly and patients can improve cognition. Available by prescription, Axona is complementary to currently approved Alzheimer’s drugs.
Accera, makers of Axona, discovers and develops breakthroughs in treating central nervous system disorders. Accera’s novel therapeutic approaches positively impact patients with neurodegenerative disorders, who are in need of effective, well-tolerated therapies. In addition to Axona, Accera is investigating therapeutic treatments for Parkinson's disease, Huntington’s disease and other age-related memory loss disorders. These products, which are based on the company’s proprietary scientific platform, are in early clinical development.
About 21st Century Health
21st Century Health is independently produced by Multi-Media Productions and is distributed worldwide on CNBC & Fox Business News (as paid programming). The show is an informative magazine style program that exhibits the hottest stories, trends and breakthroughs that will educate and motivate our viewers. For specific market-by-market air dates and times, please e-mail moniqueh@mmpusa.com. For more information, please visit www.21chtv.com
For airing information, go to
http://www.21cbtv.com/1945fbn.pdf
Axona has been shown in randomized, placebo controlled clinical trials to safely improve cognitive function and memory in patients diagnosed with mild-to-moderate AD. It provides an alternative energy source for the brain so that neurons can function properly and patients can improve cognition. Available by prescription, Axona is complementary to currently approved Alzheimer’s drugs.
Accera, makers of Axona, discovers and develops breakthroughs in treating central nervous system disorders. Accera’s novel therapeutic approaches positively impact patients with neurodegenerative disorders, who are in need of effective, well-tolerated therapies. In addition to Axona, Accera is investigating therapeutic treatments for Parkinson's disease, Huntington’s disease and other age-related memory loss disorders. These products, which are based on the company’s proprietary scientific platform, are in early clinical development.
About 21st Century Health
21st Century Health is independently produced by Multi-Media Productions and is distributed worldwide on CNBC & Fox Business News (as paid programming). The show is an informative magazine style program that exhibits the hottest stories, trends and breakthroughs that will educate and motivate our viewers. For specific market-by-market air dates and times, please e-mail moniqueh@mmpusa.com. For more information, please visit www.21chtv.com
For airing information, go to
http://www.21cbtv.com/1945fbn.pdf
Contact Information:
Multi-Media Productions USA
Viola Malone
Tel: 561-988-9449 x228
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
Multi-Media Productions USA
Viola Malone
Tel: 561-988-9449 x228
Email us
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.
|
Private Equity, Angel Investing
Equity Alliance / Private Equity, Angel Investing, / IPO, Venture Capital & IR services / Equity Alliance International Equityallianceir.com Penny Stocks to Watch Sign up for hot penny stock picks Gains of 500%+ possible! Premiumstockpicks.com/landing/ Your text Ads & PR Text Ads plus unlimited press releases, One release featured/Day for only $575 per month. Read more on Text Ads & PR Your text Ads Here! Text Ads are only $289 per month. Ads are placed same day. More on Text Ads Advertising |